CD282

CD282NCBI

IgG2a

CHO-TLR2 cells.

This product recognises human TLR2 otherwise known as CD282. TLR2 is a member of the Toll-like receptor (TLR) family and is expressed primarily by peripheral blood monocytes. TLRs are expressed on the cell surface and the endocytic compartment and recognize pathogen-associated molecular patterns (PAMPs) that are expressed on infectious agents. They also initiate cell signalling to induce production of cytokines necessary for the innate immunity and subsequent adaptive immunity. TLR2 is reported to respond to a diverse range of bacterial cell wall components mediating the innate immune response in co-operation with MD-2. Clone TL2. 1 is reported to block TLR2 function. Removal of sodium azide is recommended prior to use in functional studies. Histology: Tonsil

Flow Cytometry - 1/10 - 1/50

Interacts with LY96 TLR2 and TLR6 via the extracellular domain. Binds MYD88 via their respective TIR domains. Interacts with TICAM1. Ligand binding induces the formation of a heterodimer with TLR1.

Highly expressed in peripheral blood leukocytes in particular in monocytes in bone marrow lymph node and in spleen. Also detected in lung and in fetal liver. Levels are low in other tissues.

Genetic variations in TLR2 are associated with suceptibility to leprosy [MIM:246300]. Leprosy is a chronic disease associated with depressed cellular (but not humoral) immunity the bacterium requires a lower temperature than 37 degrees Celsius and thrives particularly in peripheral Schwann cells and macrophages. The Trp-677 polymorphism in the intracellular domain of TLR2 has a role in susceptibility to lepromatous leprosy. Wild-type TLR2 mediates CD14-enhanced Mycobacterium leprae-dependent activation of NFKB1 but TLR2 containing the Trp-677 polymorphism did not. The impaired function of the Trp-677 polymorphism provides a molecular mechanism for the poor cellular immune response associated with lepromatous leprosy.

Contains 14 LRR (leucine-rich) repeats.